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DEFINITION AND PREVALENCE
Gestational diabetes mellitus is defined as carbo-
hydrate intolerance of variable severity with onset
or first recognition during pregnancy. This defini-
tion is applicable regardless of whether insulin is
used to treat the disease or even if the condition
persists after pregnancy. It does not exclude the
possibility that unrecognized glucose intolerance
may have antedated the pregnancy.1 This defini-
tion is a misnomer, since it includes unrecognized
overt diabetes mellitus that may have existed be-
Abstract
Hyperglycemia in pregnancy, or formerly known as gestational dia-
betes mellitus, is defined as carbohydrate intolerance of variable se-
verity with onset or first recognition during pregnancy. The classical
screening and diagnosis of hyperglycemia in pregnancy is the two-
steps screening, consists of 50 gram glucose load and follow by 3-
hour 100 gram oral glucose test for those who were screening posi-
tive. The diagnosis of hyperglycemia in pregnancy is made if at least
two abnormal elevated values i.e. fasting > 95 mg/dl, 1 hour > 180
mg/dl. 2 hour > 155 mg/dl, and 3 hour > 140 mg/dl.
The International Association of Diabetes and Pregnancy Study
Groups Consensus Panel (IADPSG) in 2010 and the American Diabe-
tes Association in 2011 change the method of screening and diag-
nostic criteria. In the new method of screening all pregnant woman,
not only the high risk group, should be screened using oral glucose
tolerance test with 75 gram of glucose. The new diagnosis criteria
need only one abnormal plasma glucose value i.e. fasting > 92 mg/dl
or 1 hour > 180 mg/dl, or 2 hour > 153 mg/dl. There is debate which
criteria should be used universally, since the new criteria will in-
crease the prevalence of hyperglycemia in pregnancy.
In most diabetic clinics, especially in the North America, besides
medical nutrition therapy, insulin remains the mainstay of treatment
for this patient. However, for those women who cannot afford insu-
lin or do not wish to take insulin, glibenclamide and metformin, may
be offered as an alternative. Most experts will prefer to use met-
formin, since it does not increase body weight and also has an insulin
sensitivity effect.
[Indones J Obstet Gynecol 2012; 36-4: 211-6]
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Abstrak
Hiperglikemi pada saat hamil, atau sebelumnya dikenal dengan nama
diabetes mellitus gestasional, didefinisikan sebagai intoleransi karbo-
hidrat yang pertama kali terjadi atau diketahui pada saat hamil. Cara
skrining yang lama dikenal dengan skrining dua tahap, terdiri atas tes
tantangan glukosa dengan beban glukosa 50 gram dan dilanjutkan
dengan tes toleransi glukosa oral beban glukosa 100 gram bagi me-
reka yang tes tantangan glukosa positif. Diagnosis hiperglikemi saat
hamil ditegakkan apabila sedikitnya ditemukan dua angka abnormal
dari hasil tes toleranssi glukosa oral yaitu puasa > 95 mg/dl, 1 jam >
180 mg/dl. 2 jam > 155 mg/dl, dan 3 jam > 140 mg/dl.
Pada tahun 2010 The International Association of Diabetes and Preg-
nancy Study Groups Consensus Panel (IADPSG) dan American Diabetes
Association pada tahun 2011 mengubah cara skrining dan kriteria di-
agnosis yang lama. Cara skrining yang baru mencakup semua wanita
hamil, tanpa memperhatikan adanya faktor risiko. Skrining dilakukan
dengan tes toleransi glukosa oral beban glukosa 75 gram. Kriteria
yang baru hanya membutuhkan satu angka abnormal dari ketiga ha-
sil tes toleransi glukosa oral yaitu puasa > 92 mg/dl, 1 jam > 180
mg/dl, dan 2 jam > 153 mg/dl. Sampai saat ini masih ada ketidak-
sepakatan kriteria mana yang seharusnya digunakan, mengingat kri-
teria baru akan meningkatkan prevalensi penderita hiperglikemi saat
hamil. Sebagian besar klinik diabetes, khususnya di Amerika Utara,
terapi nutrisi medik dan insulin masih merupakan pilihan pengobatan
yang digunakan. Apabila penderita tidak dapat menggunakan insulin
atau tidak mau suntikan insulin, obat antidiabetik oral seperti
glibenklamid dan metformin merupakan terapi alternatif. Keba-
nyakan ahli memilih menggunakan metformin, oleh karena selain ti-
dak meningkatkan berat badan juga mempunyai efek memperbaiki
sensitivitas insulin di jaringan.
[Maj Obstet Ginekol Indones 2012; 36-4: 211-6]
Kata kunci: hiperglikemi pada kehamilan, kriteria IADPSG, terapi far-
makologik
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fore pregnancy and hyperglycemia that is diag-
nosed concurrently with pregnancy. Because the
term of gestational diabetes mellitus is confusing,
the International Association of Diabetes and Preg-
nancy Study Groups Consensus Panel (IADPSG)
used the term of "hyperglycemia in pregnancy".2 In
this paper we used the term hyperglycemia in
pregnancy instead of gestational diabetes mellitus.
The prevalence of hyperglycemia in pregnancy
varies due to several factors i.e. the criteria used
for the screening, the pregnant women itself either
all pregnant women or only the high risk group,
the different of ethnic groups. In the last two dec-
ades diabetes mellitus is increased all over the
world especially among the developing countries.
One of the important reason is the increasing of
obesity due to changes of lifestyles. Since the
prevalence of type 2 diabetes mellitus is increasing,
which is mostly cause by insulin resistance, the
condition of hyperglycemia in pregnancy may also
increased. In the 1960s, using the same criteria of
diagnosis, the prevalence of hyperglycemia in preg-
nancy was around 1- 4%, the current estimates is
between 7 - 14%.3 In Indonesia 1982 the preva-
lence of diabetes mellitus in Indonesia was only
1.5%,4-6 while in the year 2000s it is increasing to
9-12%.7,8 Our own study in Makassar in 1989, the
prevalence of gestational diabetes mellitus varies
between 2.3%.9 With the increasing of type 2 dia-
betes mellitus and obesity in Indonesia in the re-
cent year, especially in women of child bearing age,
the prevalence of hyperglycemia in pregnancy will
also increased.
SCREENING AND DIAGNOSIS
For many years, the American Diabetes Association
(ADA) as well as other countries used a two-step
screening and diagnosis of hyperglycemia in preg-
nancy. This method of screening and diagnosis of
gestational diabetes mellitus was the gold standard
in the United States.10 The two-step screening ap-
proach consist of first step, the initial screening by
measuring the plasma glucose 1- hour after a 50
gram glucose load. The test is positive when the
plasma glucose level > 140 mg/dl. Those with posi-
tive test will be followed by the second step, the 3
- hour 100 gram oral glucose tolerance test. Gesta-
tional diabetes mellitus (the old terminology) was
diagnosed if at least two of the four values equal
or exceed the cut points of fasting plasma glucose
> 95 mg/dl, 1-hour after 100 g glucose of 180
mg/dl, 2-hour of 155 mg/dl, and 3-hour of 140
mg/dl (Figure 1).
Due to the increasing prevalence of obesity
among child bearing age women, the number of
women with hyperglycemia in pregnancy will also
increase, which carries risks for the mother and
also the fetus. The Hyperglycemia and Adverse
Pregnancy Outcome (HAPO) study, a multinational
epidemiologic study consist of more than 25,000
pregnant women, proved that risk of complication
among the mother, fetal, and neonatal continuously
increased as an increasing maternal glycemia at
24-28 gestational weeks, even within ranges of
previously considered as a normal glycemic range
for pregnant women.11 The results of HAPO study,
led to careful reconsideration of the old diagnosis
criteria of hyperglycemia in pregnancy. The conclu-
sion of the HAPO study, gave a new cutoffs point
for a new criteria of diagnosis hyperglycemia in
pregnancy, the fasting plasma glucose ≥ 92 mg/dl,
1-h ≥ 180 mg/dl, and 2-h ≥ 153 mg/dl. The IADPSG
in March 20102 and ADA in 2011,12 recommend as
follow a) all women not known have prior diabetes
mellitus, should undergo a 75 gram OGTT at 24-28
weeks of gestation, b) the diagnosis criteria of hy-
perglycemia in pregnancy follow the result of the
HAPO study i.e fasting plasma glucose > 92 mg/dl,
1-h > 180 mg/dl, and 2-hour > 153 mg/dl (Table
1). Table 1 shows the difference between the old


















Figure 1.  The two step screening and diagnosis of hyper-
glycemia in pregnancy.
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This new criteria, the IADPSG criteria, will sig-
nificantly increase the prevalence of hyperglycemia
in pregnancy, primarily because only one abnormal
value is needed for the diagnosis. Agarwal et al13
in their study of 10.283 pregnant women undergo-
ing a 75-gram glucose OGTT reported that using
the IADPSG will increase the prevalence of hyper-
glycemia in pregnancy nearly three fold compared
to the old ADA criteria.
Treatment goals and methods of treatment
Maternal hyperglycemia with resultant of fetal hy-
perinsulinemia is central to the pathophysiology of
all diabetic complications during pregnancy and
delivery. The infants of mother with hyperglycemia
in pregnancy are at 3 to 8 fold increased risk still-
birth and macrosomia, spontaneous abortion, con-
genital anomalies, metabolic complications (hypo-
glycemia and hypocalcemia), haematologic compli-
cations (hyperbilirubinemia and polycytemia), and
shoulder dystocia after delivery. These side effects
may occur even in a mild hyperglycemia during
pregnancy. The Australian Carbohydrate Study in
Pregnant Women (ACHOIS) trial, proved that treat-
ment of hyperglycemia in pregnancy reduces seri-
ous perinatal morbidity.14
Good glycemic control may achieve by exercise
and medical nutrition therapy, plus pharmacologic
therapy if fail by medical nutrition therapy. Al-
though normoglycemia is the accepted goals of
treatment in hyperglycemia in pregnancy, the tar-
get goals of blood sugar is still controversies. The
ADA suggest the treatment goals is to maintain
normoglycemia i.e fasting plasma glucose < 95
mg/dl, 1-h postprandial plasma glucose ≤ 140
mg/dl, and 2-h postprandial ≤ 120 mg/dl.15 The
National Institute for Health and Clinical Excellence
(NICE) recommendation for self testing of blood
sugar in pregnancy is fasting 63 - 106 mg/dl and
1-hour after postprandial should be < 140 mg/dl.16
Another guideline, the Canadian Diabetes Associa-
tion recommends fasting plasma glucose 3.5 to 5.2
mmol/l, 1 hour postprandial 5.5 - 7.7 mmol/l, and
2 hour postprandial 5.0 - 6.6 mmol/l. In our clinic,
we use the ADA criteria and all patient with hyper-
glycemia in pregnancy are advised to have a reflec-
tance meter for self-monitoring of capillary blood
sugar at home.
Most patient with hyperglycemia in pregnancy
will reach the normoglycemia levels only by life-
style modification, the medical nutrition therapy
and exercise. In our clinic only 15% of them need
pharmacologic therapy with insulin.
Insulin
After fails to medical nutrition therapy, around 80-
90% of hyperglycemia in pregnancy   need insulin
therapy. Since the use of insulin in 1922, the peri-
natal mortality rate decreased near to non-diabetic
pregnancy (Figure 2).17 At the moment we have
two kinds of insulin, the human insulin and the
analogues insulin. Human insulin has been used for
years, and it is safe since it does not transfer to
placenta. The analogues insulin has several bene-
fits compared to human insulin such as greater
convenience in he timing of injection (just before
meals while human insulin should be 30 minutes
before meals), less hypoglycemia effects. Until now,
there are only three analogues insulin agreed to
use in pregnancy, insulin lispro (Humulin), insulin
aspart (Novorapid) and glargin (Lantus).18-20
Table 1. The old and the new criteria for the diagnosis of hyperglycemia in pregnancy
Old method New method
24-28 weeks Screen high-risk all women gestation Universal testing of all pregnant women
Screen 1-h 50-g glucose load, nonfasting, glucose
loading test; if ≥ 130 or 140, proceed to
diagnostic test
None
Diagnostic test After 8- to 12-h fast, obtain fasting provide
100-g glucose load; then obtain 1-, 2-, and 3-h
venous BG
After 8- to 12-h fast, obtain fasting, provide
75-g glucose load, then obtain 1-, and 2-h
venous BG
Diagnostic of GDM If two of the following values meet or exceed:
fasting 95 mg/dl, 1-h 180 mg/dl, 2-h 155
mg/dl, 3-h 140 mg/dl
If any 1 values meets or exceeds: fasting 92
mg/dl, 1-h 180 mg/dl 2-h 153 mg/dl
Data from American Diabetes Association. Standards of medical care in diabetes 2011. Diabetes Care 2011; 34 (suppl 1): S11-S61.
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The dose of insulin depends of the bodyweight
of the patient before pregnancy. In non-obese pa-
tients insulin dose is 0,8 U/kg, but for obese sub-
jects insulin requirement is 0,9 U/kg. The admini-
stration of insulin depends on the fluctuation of
blood sugar. For many patients with hyperglycemia
in pregnancy, increase of fasting plasma glucose is
the only abnormal glucose value. In such patients,
a single morning injection of 10 U long-acting in-
sulin such NPH insulin is sufficient to achieve
euglycemia throughout 24 hour. For some patients
may need more than one injection such as fixed-
dose combination of 70% intermediate acting in-
sulin and 30% of short acting insulin.15 It is advised
to reach this strict target goals, self-monitoring of
blood glucose before every insulin injection is rec-
ommended.
Oral Hypoglycemic Agents
The use of oral hypoglycemic agents in patients
with hyperglycemia in pregnancy has been one of
the biggest controversies in the treatment of dia-
betes and pregnancy. A variety of oral hypoglyce-
mic agents is now available for lowering blood glu-
cose. For patients with pregnancy and hyperglyce-
mia, the most important is that the agent should
not cross the placenta from the maternal to fetal
circulation in significant amounts. Because most
patients with hyperglycemia in pregnancy were
identified between 24 - 28 of gestation, the fetus
is not exposed to the drug during the period of or-
ganogenesis.
The first report using oral hypoglycemic agents
in patients with diabetes and pregnancy was re-
ported by Coetzee et al from Cape Town South Af-
rica in 1974.21 In their study, metformin and gly-
benclamide were used. Metformin was used for
obese patients and glibenclamide for normoweight.
From their study, the conclusion was using oral hy-
poglycemic agent, either metformin or gliben-
clamid was better compared to those only in die-
tary treatment or without treatment. In their study
the conclusion was "we believe that the secret of
successful perinatal outcomes in all pregnant dia-
betic patients lies more in the achievement of excel-
lent blood glucose levels than in the means of achiev-
ing it". For several years, around 25 years, there
was no publication about oral hypoglycemic agents
in diabetes and pregnancy.
Glibenclamide
Glibenclamide or glyburide in USA, was used for
the treatment for hyperglycemia in pregnancy
since it is less crossing the placenta (only 3.9%)
compared to the other sulfonylurea agents. Langer
et al22 in 2000 for the first time reported their
study to compare glybenclamide and insulin in pa-
tients with hyperglycemia in pregnancy. The
authors compared glybenclamide and standard in-
sulin therapy in randomized control trial of 404 pa-
tients. The target goals for glucose was fasting 60-
90 mg/dl, prepradial 80-95 mg/dl, and 2-h post-
prandial < 120 mg/dl. The results of their study
was the perinatal morbidity such as incidence of
macrosomia, neonatal metabolic complications (hypo-
glycemia, polycythemia, hyperbilirubinemia) respi-
ratory distress and cesarian delivery, are compara-
ble between the two groups. If the patient fail to
reach the target goals than they have to be
switched to insulin therapy. The failure rates with
glybenclamide was reported between 16 to 21%,
mostly due to poor glycemi control and some by
hypoglycemia effect in the mother.
Metformin
Different than glibenclamide, metformin can re-
duce the blood sugar by reducing hepatic glucose
output from the liver, increasing peripheral glucose
uptake by the liver, muscle and adipose tissues.
The actions of this agent does not cause insulin se-
cretion hence does not cause hypoglycemic effect.
Rowan and his colleagues23 (MiG Trial Investiga-








Figure 2.  The reduction of perinatal mortality after the era
of insulin.17
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tion) in 2008 published their study on metformin
in hyperglycemia in pregnancy. In this study 751
patients were randomized to two different treat-
ment either metformin or insulin. The rate of pri-
mary composite outcome of neonatal morbidity, in-
cluded neonatal hypoglycemia, respiratory dis-
tress, prematurity, and birth trauma was not
significant different between the two groups, for
the metformin group was 32.0% and insulin group
32.2%. One important results which is different be-
tween the two groups was severe hypoglycemia in
the neonatal, only 3.3% among the metformin
treatment and 8.1% in the insulin therapy.
The Controversies of Treatment
Even if the patient with hyperglycemia in preg-
nancy does not have high abnormal glucose intol-
erance, all experts agree that treatment either by
lifestyle modification only, or lifestyle modification
plus pharmacologic treatment is always needed to
reach the excellent target goals. For years insulin
was the only treatment of choice for this patient.
The choice of insulin is still controversy, especially
the used of insulin analogue. This kind of insulin
used in pregnant diabetic patients just started 10
years ago. The human insulin is preferable since it
has been used for years without side effect in the
neonates or even long-term effect among the chil-
dren.
The use of oral agents, metformin and gliben-
clymide, is still the biggest controversy in diabetol-
ogy. American Diabetes Association in the recent
Clinical Practice Recommendation 2012,24 the di-
agnosis of women with hyperglycemia follow the
new criteria but there was no statement about the
treatment, which means that insulin is still the only
pharmacologic therapy. In 2009 the International
Diabetes Federation of World Health Organization
statement as follow "for women with GDM who ex-
ceed predetermined glycemic goals, insulin is the
preferred treatment. Where insulin cannot be af-
forded, or where circumstances make its use haz-
ardous, then oral agents can be the only option".
In our clinic, insulin is still the only choice for the
treatment diabetic patients complicated with hy-
perglycemia.
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